We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Eye Care

Journal Scan / Research · January 24, 2023

Real-World Cost-Effectiveness of Anti-VEGF Monotherapy vs Combination Therapy for Patients With Polypoidal Choroidal Vasculopathy

Eye (London, England)


Additional Info

Eye (London, England)
Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy
Eye (Lond) 2022 Dec 01;36(12)2265-2270, J Chay, BJ Fenner, EA Finkelstein, KYC Teo, CMG Cheung

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading